



Contents lists available at ScienceDirect

Antiviral Research

journal homepage: www.elsevier.com/locate/antiviral



Meeting Report

Meeting report: 27th International conference on antiviral research

R. Anthony Vere Hodge*

Vere Hodge Antivirals Ltd, Old Denshott, Leigh, Reigate, Surrey, UK

ARTICLE INFO

Article history:
Received 15 August 2014
Accepted 18 August 2014
Available online xxxx

Keywords:

Human immunodeficiency virus
Hepatitis B virus
Hepatitis C virus
Ebola virus
Antiviral therapy

ABSTRACT

The 27th International Conference on Antiviral Research (ICAR) was held in Raleigh, North Carolina, USA from May 12 to 16, 2014. This article summarizes the principal invited lectures. John Drach (Elion Award) described the early days of antiviral drugs and their novel modes of action. Piet Herdewijn (Holý Award) used evolutionary pressure to select DNA polymerases that accept nucleoside analogs. Replacing thymine by 5-chlorouracil led to the generation of a new form of *Escherichia coli*. Adrian Ray (Prusoff Award) demonstrated how prodrugs can markedly improve both the efficacy and safety of potential drugs. The keynote addresses, by David Margolis and Myron Cohen, tackled two emerging areas of HIV research, to find an HIV “cure” and to prevent HIV transmission, respectively. These topics were discussed further in other presentations – a cure seems to be a distant prospect but there are exciting developments for reducing HIV transmission. TDF-containing vaginal rings and GSK-744, as a long-lasting injection, offer great hope. There were three mini-symposia. Although therapy with TDF/FTC gives excellent control of HBV replication, there are only a few patients who achieve a functional cure. Myrcludex, an entry inhibitor, is active against both HBV and HDV. The recent progress with HBV replication in cell cultures has transformed the search for new antiviral compounds. The HBV capsid protein has been recognized as key player in HBV DNA synthesis. Unexpectedly, compounds which enhance capsid formation, markedly reduce HBV DNA synthesis. The development of BCX4430, which is active against Marburg and Ebola viruses, is of great current interest.

© 2014 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/3.0/>).

Contents

47	1. Introduction	00
48	2. Gertrude Elion memorial award lecture: collaborative antiviral studies for the discovery of drugs to treat cytomegalovirus infections.	00
49	3. The Antonín Holý memorial award lecture: from modified nucleoside to a chemically modified genome	00
50	4. The William Prusoff young investigator award lecture: use of nucleotide prodrugs to enhance selectivity of anti-HIV and -HCV agents	00
51	5. Keynote addresses	00
52	5.1. Eradication therapies for HIV: building the critical path	00
53	5.2. HIV prevention 2014–2021: managing aspiration and expectation.	00
54	6. Mini-symposium: hepatitis B virus.	00
55	6.1. Hepatitis B treatment: challenges and opportunities	00
56	6.2. The hepatitis B virus life cycle: recent achievements and challenges	00
57	6.3. Immune regulation and co-stimulation in HBV-infected patients: an uneasy truce.	00
58	6.4. Diversifying the hepatitis B pipeline: current efforts to explore novel mechanisms	00
59	6.5. HBV capsid protein: biology and potential as a drug target for anti-virals.	00
60	6.6. Targeting cccDNA to cure chronic hepatitis B.	00
61	6.7. Animal models of hepatitis B disease	00
62	7. Mini-symposium: Research Triangle Park	00
63	7.1. Biophysical mechanisms and methods of evaluation in HIV prevention science	00
64	7.2. Novel animal model platforms of human disease.	00
65	7.3. Did we put the cart before the horse? Clinical pharmacology insights into HIV prevention trial outcomes	00

* Tel.: +44 (0) 1306 611212.
E-mail address: ISAR@courtesyassoc.com

66	7.4. The novel nucleoside analog BCX4430 exhibits broad-spectrum antiviral activity and confers post-exposure protection against Ebola and Marburg viruses	00
67		
68	8. Challenges in HIV infection, treatment and prevention	00
69	8.1. Can we cure HIV infection?	00
70	8.2. Potential therapeutic approaches for the cure of HIV infection	00
71	8.3. Animal models of HIV infection	00
72	8.4. Monitoring HIV drugs and viral reservoirs	00
73	9. Conclusion	00
74	10. Uncited references	00
75	Acknowledgements	00
76	References	00

1. Introduction

This article provides an overview of the invited lectures at the 27th International Conference on Antiviral Research, sponsored by the International Society for Antiviral Research (ISAR), which was held in Raleigh, North Carolina, USA from May 12 to 16, 2014. It begins with reports of lectures by the recipients of ISAR's three major awards, held in memory of Gertrude Elion, Antonín Holý and William Prusoff. These are followed by brief summaries of the keynote addresses and the three mini-symposia on "Hepatitis B virus", "Research Triangle Park" and "Challenges in HIV infection, treatment and prevention". Because this review article simply provides short accounts of oral presentations, it is not generally accompanied by references to the scientific literature. Any descriptions of favorable treatment outcomes should not be taken as recommendations for clinical use.

2. Gertrude Elion memorial award lecture: collaborative antiviral studies for the discovery of drugs to treat cytomegalovirus infections

John C. Drach, Ph.D., University of Michigan, Ann Arbor, Michigan, USA (Fig. 1).

Gertrude B. (Trudy) Elion was born in New York City and was pleased to work for the Burroughs Wellcome Co. when based in New York but was concerned when it transferred to Research Triangle Park, North Carolina, not many miles from this year's meeting site. However, within just a few months she declared that she was "at home" in North Carolina. She was awarded the Nobel Prize in Physiology or Medicine in 1988 for her pioneering work in purine biosynthesis which paved the way for the discovery of drugs to treat organ rejection, cancer and viral diseases.



Fig. 1. Phil Furman presenting the Elion Award to John Drach.

The focus of John's presentation was on the research conducted in his own and his collaborators' laboratories that ultimately led to the invention of three compounds which were discovered to have antiviral activity against human cytomegalovirus (HCMV) and which later entered clinical trials: BDCRB pyranoside (GW275175X) (Phase I), maribavir (Phases I, II and III) and cyclopropavir (Phase I). His major collaborators included Karen Biron, Charles Shipman, Leroy Townsend, and Jiri Zemlicka. To date, there are only five FDA-approved drugs for treatment of HCMV infections: cidofovir, fomivirsen, foscarnet, ganciclovir and valganciclovir.

Being inspired by the presence of a naturally-occurring 5,6-dimethylbenzimidazole nucleotide in Vitamin B12, research on benzimidazole nucleosides was initiated by medicinal chemists in the 1950s and '60s. This led to the synthesis of a trichloro analog in Townsend's laboratory at the University of Utah and later the discovery of its activity against HCMV in John's laboratory. Much work, in both their laboratories at the University of Michigan, established that it and its 2-bromo analog (BDCRB) have excellent activity against HCMV with very low cytotoxicity. Surprisingly, it was found to be inactive against other herpes viruses and it did not need conversion to a triphosphate to be active against HCMV. Collaborative studies with Karen Biron at Burroughs Wellcome established that, unlike many other anti-virals that inhibit viral DNA synthesis such as ganciclovir (GCV), these compounds acted by a novel mechanism, inhibition of viral DNA processing. It was the viral resistance studies which revealed the viral targets, pUL89 and pUL56. These two proteins, with pUL104, form a




Fig. 2. Structures of BDCRB, BDCRB pyranoside and maribavir.

Download English Version:

<https://daneshyari.com/en/article/5822145>

Download Persian Version:

<https://daneshyari.com/article/5822145>

[Daneshyari.com](https://daneshyari.com)